EASL Roundup

April 2012
BioWorld Today;4/20/2012, Vol. 23 Issue 77, p8
The article reports on the results from a Phase III open-label trial of two anemia management strategies conducted by Merck and Co. Inc. for patients in treatment with Victrelis (boceprevir) and Pegintron (peginterferonalfa-2b) and ribavirin for hepatitis C virus.


Related Articles

  • Success of Vaccine Offers Promise of Cervical Cancer Prevention. Schultz, James // JNCI: Journal of the National Cancer Institute;1/15/2003, Vol. 95 Issue 2, p103 

    Cites the key findings of Merck and Company Inc.'s clinical trials on an investigational vaccine against the human papillomavirus type 16. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cervical cancer prevention.

  • Clinic Roundup.  // BioWorld Today;12/19/2011, Vol. 22 Issue 243, p7 

    This section offers news briefs on clinical trials including the preliminary data obtained by Advaxis Inc. from a Phase II trial of ADXS-HPV, the trial initiated by Merck & Co. Inc. and Roche AG to test drug combinations for chronic hepatitis C virus genotype 1 infection, and enrollment...

  • Merck reports encouraging results from Phase IIb insomnia study.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p17 

    The article reports on the results of the Phase IIb clinical trial conducted by Merck & Co. Inc. which showed that dual orexin receptor antagonist is effective for treatment of primary insomnia.

  • Merck Pulls the Plug on Depression Drug.  // Chemical Market Reporter;11/17/2003, Vol. 246 Issue 17, p2 

    Reports that Merck & Co. Inc. stopped the development of an investigational depression drug, MK-0869, after it failed to show efficacy in Phase III trials. Drugs sales of the company; Mode action of MK-0869; List of phase III products remaining in the Merck pipeline.

  • Merck, Pfizer combining drugs. Investor's Business Daily // Investors Business Daily;8/27/2014, pA02 

    The article reports on the plan of pharmaceutical company Merck & Co. Inc. to conduct clinical trials for brolizumab, an immunotherapy drug .

  • Packs more punch. Horton, Kathleen // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p100 

    Announces Merck & Co. Inc.'s presentation of the findings of the Phase III clinical trials on the anti-migraine drug Maxalt 10 mg (rizatriptan) at the 8th Congress of the International Headache Society.

  • MERCK & CO.  // MondayMorning;1/24/2011, Vol. 19 Issue 3, p11 

    The article reports on Merck & Co. Inc.'s decision of halting the study of anticlotting pill vorapaxar following the bleeding risks to patients with a history of strokes. It reports that the company stopped the study as the drug was linked to an increased risk of intracranial hemorrhage in...

  • Merck Launches Alzheimer's Trial.  // MondayMorning;12/10/2012, Vol. 20 Issue 47, p1 

    The article reports on the launch by Merck & Co. of a late-stage study on the treatment of Alzheimer's disease.

  • Bad seed? Critics say drug study more marketing than medicine.  // IRB Advisor;Nov2008, Vol. 8 Issue 11, p121 

    The article discusses the Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness (ADVANTAGE). It is suspected to be a seeding trial but Merck denied it by emphasizing the purpose of examining Vioxx. A seeding trial refers to a clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics